CLOs on the Move

NorthStar Medical Radioisotopes

www.northstarnm.com

 
NorthStar® Medical Radioisotopes is a nuclear medicine technology company dedicated to transforming the ways that medical radioisotopes are produced and distributed around the world.
  • Number of Employees: 250-1000
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Infinity Care Solutions

Infinity Care Solutions wants to take the time and trouble out of a normal pharmacy experience by not only providing you with traditional medications, but also offering you and your healthcare provider a choice. We know that no two patients are exactly the same and each requires specific knowledge and a team approach. It is our goal to meet this challenge head on. With our top-of-the-line, custom-made compounded products, and our impeccable customer service, our mission is for you to experience symptom relief like never before. Our pharmacy is built on a solid foundation of medical expertise and cutting edge pharmaceutical compounding methods that are unmatched, especially in the areas of topical hormone replacement therapy and topical pain medications.

Savage Laboratories

Savage Laboratories is a Melville, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Micron Technologies

Micron Technologies is a Exton, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pharma Logistics

Pharma Logistics is a Mundelein, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

ProNAi

ProNAi Therapeutics is a clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNAi technology platform for patients with cancer and hematological diseases. ProNAi`s lead DNAi product candidate, PNT2258, is designed to treat cancers that overexpress BCL2, an important and validated oncogene known to be dysregulated in many types of cancer. ProNAi is pursuing a multi-faceted clinical development strategy designed to efficiently achieve regulatory approval and maximize the commercial opportunity of PNT2258. ProNAi recently initiated "Wolverine", a Phase 2 trial evaluating PNT2258 for the treatment of relapsed or refractory diffuse large B-cell lymphoma.